An alarming rate of cancer clinical trials ending early
Last week, Cambridge, Mass.-based Aveo Oncology and Astellas Pharma Inc., of Tokyo, announced that they were discontinuing a Phase II trial testing tivozanib in patients with locally recurrent or metastatic triple negative breast cancer due to insufficient enrollment.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter